Background: PSE has been safely used to improve hypersplenism–related thrombocytopenia by reducing the splenic volume using conventional transarterial superselective embolization technique. PSE provides an increase in hematologic indices to facilitate initiation and continuation of SC in oncological patients who are not surgical candidates and for whom splenectomy is contraindicated.
OBJECTIVE: The aim of this study is to evaluate 1ry, 2ry end points, technical parameters, outcomes and complications of PSE in oncological patients with hypersplenism-related thrombocytopenia requiring SC.
METHODS: This retrospective study comprised 24 oncological patients (18 males and 6 females; their ages ranged 35–70 years old), they underwent PSE for correcting thrombocytopenia in order to initiate (n=6) or continue (n=18) their optimally dosed SC. The 1ry endpoint was the achievement of a platelet count >130×〖10〗^9/L and the 2ry endpoint was the initiation or continuation of SC.
RESULTS: Mean platelet count prior to PSE was 69.08 ± 3.54 ×109/L (range 62–75×109/L).The percentage of splenic necrosis was estimated by angiography, mean post-PSE splenic infarction percentage was 58.33 ± 8.16 %. Mean platelet counts at days 10, 20 and 30 post-PSE were 273.58±77.30×109/L, 218.54±60.06×109/L and 157.16±44.90×109/L, respectively (P